| Style | Citing Format |
|---|---|
| MLA | Varshosaz J, et al.. "Encapsulation of Imatinib in Targeted Kit-5 Nanoparticles for Reducing Its Cardiotoxicity and Hepatotoxicity." Anti-Cancer Agents in Medicinal Chemistry, vol. 20, no. 16, 2020, pp. 1966-1980. |
| APA | Varshosaz J, Fardshouraki S, Mirian M, Safaeian L, Jandaghian S, Taymouri S (2020). Encapsulation of Imatinib in Targeted Kit-5 Nanoparticles for Reducing Its Cardiotoxicity and Hepatotoxicity. Anti-Cancer Agents in Medicinal Chemistry, 20(16), 1966-1980. |
| Chicago | Varshosaz J, Fardshouraki S, Mirian M, Safaeian L, Jandaghian S, Taymouri S. "Encapsulation of Imatinib in Targeted Kit-5 Nanoparticles for Reducing Its Cardiotoxicity and Hepatotoxicity." Anti-Cancer Agents in Medicinal Chemistry 20, no. 16 (2020): 1966-1980. |
| Harvard | Varshosaz J et al. (2020) 'Encapsulation of Imatinib in Targeted Kit-5 Nanoparticles for Reducing Its Cardiotoxicity and Hepatotoxicity', Anti-Cancer Agents in Medicinal Chemistry, 20(16), pp. 1966-1980. |
| Vancouver | Varshosaz J, Fardshouraki S, Mirian M, Safaeian L, Jandaghian S, Taymouri S. Encapsulation of Imatinib in Targeted Kit-5 Nanoparticles for Reducing Its Cardiotoxicity and Hepatotoxicity. Anti-Cancer Agents in Medicinal Chemistry. 2020;20(16):1966-1980. |
| BibTex | @article{ author = {Varshosaz J and Fardshouraki S and Mirian M and Safaeian L and Jandaghian S and Taymouri S}, title = {Encapsulation of Imatinib in Targeted Kit-5 Nanoparticles for Reducing Its Cardiotoxicity and Hepatotoxicity}, journal = {Anti-Cancer Agents in Medicinal Chemistry}, volume = {20}, number = {16}, pages = {1966-1980}, year = {2020} } |
| RIS | TY - JOUR AU - Varshosaz J AU - Fardshouraki S AU - Mirian M AU - Safaeian L AU - Jandaghian S AU - Taymouri S TI - Encapsulation of Imatinib in Targeted Kit-5 Nanoparticles for Reducing Its Cardiotoxicity and Hepatotoxicity JO - Anti-Cancer Agents in Medicinal Chemistry VL - 20 IS - 16 SP - 1966 EP - 1980 PY - 2020 ER - |